Anti-tgf-beta receptor ii antibodies

Abstract

The present invention is directed to antibodies against human transforming growth factor beta receptor II (TGFPRII), including an antibody comprising a CDRH1 having the sequence GGSISNSYF (SEQ ID NO: 1); a CDRH2 having the sequence S£YYGEKTYYNPSLKS (SEQ ID NO: 2); a CDRH3 having the sequence GPTMIRGVIDS (SEQ ID NO: 3); a CDRL1 having the sequence RASQSVRSYLA (SEQ ID NO: 10); a CDRL2 having the sequence DASNRAT (SEQ ID NO: 11); and a CDRL3 having the sequence QQRSNWPPT (SEQ ID NO: 12) and pharmaceutical compositions comprising antibodies and methods of using the antibodies, alone or in combination, for example, for treating cancer and fibrosis.